Imfinzi has received priority review by the FDA for the treatment of lung cancer 

AstraZeneca on Thursday the US Food and Drug Administration (FDA) said its top-selling cancer drug Imfinzi has received priority review for patients with limited-stage small-cell lung cancer in the United States.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM